Chronic obstructive pulmonary disease
Conditions
Interventions
Treatment group:Granule of No.2 Jianpi Yifei
Control group:Placebo of No.2 Jianpi Yifei
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 40 to 85 years, both men and women; 2. According to COPD criteria defined by GOLD, grade II to IV, and after post-bronchodilators, FEV1% between 20% to 80%; 3. TCM syndrome differentiation is Qi deficiency syndrome or deficiency of Qi; 4. Patients with cough, sputum, dyspnea and other symptoms, these symptoms are stable or slight, for at least 2 weeks; 5. There have been at least one acute exacerbation of patients in the last 1 years; 6. Patients signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Those with a history asthma, bronchial dilation and so on; 2. Those with a history of chronic systemic infections or inflammatory conditions that required systematic corticosteroid treatment in the last 3 months; 3. TCM syndrome differentiation with Yin deficiency as the main syndrome; 4. Chest imaging shows that there is a lung infection, pulmonary mass, or other features that judged it is not fit into the group; 5. Patients with malignant tumor, diabetes, acute peptic ulcer or bleeding, or other serious diseases, and the researchers estimate that it is not suitable to participate in the study; 6. Those who are not willing to accept the observation measures or because of mental illness can not cooperate; 7. Individuals unable to adequately perform spirometry tests; 8. Those who start taking Jianpi Yifei medicine before 2 weeks in the study, or individuals having pulmonary rehabilitation within three months of the commencement of the study, or intend to enter pulmonary rehabilitation during the study; 9. Pregnancy, breast-feeding or women intending to become pregnant during the course of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SGRQ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of COPD acute exacerbation;Time to first exacerbation;Acute exacerbation rate;Severity of acute exacerbation;6WMT;BODE index;Lung function;CAT;SpO2; | — |
Countries
China
Contacts
Public ContactLin Lin
Outcome results
None listed